CYP51A1 and Chagas disease: Although inhibitors of the fungal sterol 14α-demethylase enzyme (CYP51) and the orthologous enzyme T. cruzi CYP51 (TcCYP51) demonstrated promising efficacy against Chagas disease in preclinical studies [11], [12], [13], data from clinical trials using posaconazole or ravuconazole were disappointing [14], [15].